Heron Therapeutics (HRTX) Other Accumulated Expenses (2012 - 2026)

Heron Therapeutics (HRTX) has 15 years of Other Accumulated Expenses data on file, last reported at $50.0 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 5.41% year-over-year to $50.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.0 million (up 5.41% YoY) and the FY2025 annual result came in at $51.2 million, up 22.71% from the prior year.
• Other Accumulated Expenses fell to $50.0 million in Q1 2026, from $51.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $52.4 million in Q2 2023 to a low of $32.7 million in Q3 2022.
• A 5-year average of $42.6 million and a median of $41.9 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses surged 58.2% — and 2024, when it declined 19.43%.
• Tracing HRTX's Other Accumulated Expenses over 5 years: stood at $38.6 million in 2022, then climbed by 8.57% to $41.9 million in 2023, then retreated by 0.24% to $41.8 million in 2024, then grew by 22.71% to $51.2 million in 2025, then declined by 2.43% to $50.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $50.0 million (Q1 2026), $51.2 million (Q4 2025), and $48.5 million (Q3 2025), per Business Quant data.